Purpose: Indoleamine 2,3 dioxygenase 1 (IDO1) mediates potent immunosuppression in multiple preclinical models of cancer. However, the basis for elevated IDO1 expression in human cancer, including the most common primary malignant brain tumor in adults, glioblastoma (GBM), is poorly understood. The major objective of this study is to address this gap in our understanding of how IDO1 expression contributes to the biology of GBM, and whether its level of expression is a determinant of GBM patient outcome.
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TRANSLATIONAL RELEVANCE
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults with a dismal prognosis. Increased IDO1 expression is associated with decreased survival among glioma patients, but the significance of IDO1 expression exclusively in GBM patients, has yet to demonstrated. This study reveals that, high IDO1 mRNA levels, as assessed using the Hi-RNA-Sequencing Illumina platform, are consistently associated with decreased GBM patient survival. It also shows that, infiltrating human T cells directly increase IDO1 expression in GBM. Given the growing number of clinical trials aimed at immunotherapeutically enhancing T cell functions in GBM, these data suggest that the further inhibition with an IDO1 inhibitor, may increase the number of individuals that respond favorably in the clinic. 
INTRODUCTION
Glioblastoma (GBM, astrocytoma, WHO grade IV) is the most common and aggressive primary central nervous system (CNS) cancer in adults (1) . Numerous efforts have been made to identify prognostic biomarkers for GBM patients, resulting in the determination of O-6-methylguanine-DNA methyltransferase (MGMT) gene promoter methylation (2, 3) , mutant isocitrate dehydrogenase 1 and 2 (mIDH1/2) (4), as well as chromosome 1p/19q co-deletion, as important indicators of tumor malignancy and/or response to specific therapies (5, 6) . Novel immunotherapies, which have caused the reconsideration of patient management among multiple malignancies including melanoma (7, 8) and lung cancer (9, 10) , have been largely unsuccessful in treating GBM.
A caveat associated with this lack of success is the relative dearth of knowledge regarding biomarkers that could be used to guide patient selection for specific immunotherapies. 
CD8
+ effector T cells (Tc), as demonstrated in preclinical GBM models (13) . The protein level and/or activity of IDO1 has been correlated with prognosis in several tumor types (14) (15) (16) (17) (18) (19) . In GBM, however, interpretations of the prognostic significance of IDO1 expression have been inconsistent, with immunohistochemical analysis revealing cellular positivity ranging from 8% to 96%, respectively (20, 21) . Additionally, while we previously demonstrated that the upregulation of IDO1 mRNA levels inversely correlate with glioma patient survival (22) , microarray-based expression analysis did not
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Here, we have compared mRNA-vs. antibody-based IDO1 detection in GBM surgical specimens, and determined a correlation between high IDO1 mRNA levels and decreased patient survival for grade II, III or IV (GBM) gliomas. Increased IDO1 mRNA was associated with a commensurate increase in the expression for cytolytic T cell markers, CD3E and CD8A, suggesting a T cell-associated influence on intratumoral IDO1 expression.
Research. 
METHODS
The cancer genome atlas (TCGA) sample description
The TCGA data for all the cancer types analyzed in current study were accessed from the UCSC Xena browser (http://xena.ucsc.edu/). mRNA expression data represented by RNASeq (Illumina Hi-seq platform) includes RSEM normalized level 3 data present in TCGA as of April 13th, 2017. DNA methylation data and exon expression RNASeq data were extracted from the same TCGA dataset. Glioma patient data were also acquired from the Molecular Brain Neoplasia Data (REMBRANDT) database (https://wiki.cancerimagingarchive.net/display/Public/REMBRANDT) as of April 13th, 2017. TCGA GBM gene expression data by AffyU133a array were also acquired from the UCSC Xena browser.
Patient samples
Peripheral blood from GBM patients were collected at the Northwestern Brain Tumor Institute (NBTI) Tissue Bank. PBMCs were isolated using Ficoll-Paque (GE Healthcare) density gradient separation and stored at liquid nitrogen tank for coculture experiments. Snap-frozen tissue and formalin-fixed, paraffin-embedded (FFPE) tissue from surgically-removed GBM were also collected at the NBTI Tissue Bank. All tumors were diagnosed according to WHO diagnostic criteria by Dr. Craig Horbinski. Detailed information for patient tissue samples used in gene expression analysis and in situ RNA hybridization /immunohistochemistry are provided in Supplementary Table 1 .
Animal and tissue preparation
Immunocompetent, humanized mice (NSG-SGM3-BLT) were established by implantation of human fetal liver and thymus fragments as well as haematopoietic stem 
Statistical analysis
The cutoff value for each gene expression level was determined with Cutoff Finder software (http://molpath.charite.de/cutoff/) using significance as the cutoff optimization method (25) . Kaplan-Meier (KM) survival analysis was performed to estimate the survival distribution, while the log-rank test was used to assess the statistical significance of differences between the stratified survival groups using GraphPad Prism 
RESULTS
Comparison of IDO1 expression by mRNA and protein detection methods in GBM
Previous studies have demonstrated highly variable IDO1 levels in GBM using immunohistochemical detection. In accordance with a recent independent report (26), minimal IDO1 protein expression was detected in both newly-diagnosed and recurrent surgical GBM specimens ( 
Patient survival and IDO1 expression in different grades of gliomas
To follow-up our previous work, we evaluated the surgical specimen cohort using ( Fig. 2A ; P < 0.0001). Interestingly, while a large subset of grade II and III glioma specimens were undetectable for IDO1 mRNA, 95% of GBM specimens possessed detectable IDO1 mRNA levels (Fig. 2B ). In contrast, IDO2 expression did not change with tumor grade and the majority of samples analyzed were undetectable for gene transcript ( Fig. 2A) . In accordance with a previous report, TDO2 mRNA levels were significantly increased in grade IV glioma (27) . Additionally, further analysis of IDO1 mRNA in GBM revealed differential exon expression for IDO1 (Supp. Fig. 3 , Supp. Table 2 ), indicating the possibility of multiple IDO1 mRNA isoforms being expressed in
GBM.
Based on the correlation between increasing glioma grade and increasing IDO1 mRNA, we examined whether high IDO1 expression correlates with patient survival using Kaplan-Meier (KM) analysis. Cutoff Finder was utilized to generate individual cutoff values within each glioma grade. IDO1 mRNA levels were stratified into IDO1-low and -high expressing groups based on the determined cutoff values. High IDO1 mRNA levels were significantly correlated with decreased patient survival across all 3 glioma patient tumor grades ( Fig. 2C ; P < 0.05). Because clinicopathologic parameters including age, tumor grade and mode of therapy can also contribute to the prognosis of glioma patients, multivariate COX regression analysis was performed to evaluate whether IDO1 mRNA levels can be utilized as an independent prognostic factor. The results indicate that, IDO1 mRNA expression functions as an independent prognostic factor in grade II and III glioma, as well as for GBM patients (Supp. Table 3 ,4, respectively; Table   1 ). Karnofsky Performance status data was missing in up to 50% of the analyzed specimens and were therefore not included in the multivariate analysis. 
IDO1 expression with respect to GBM subtype and IDH1 mutation status
Given the commonly used transcriptome-based classification of GBM (28), we examined IDO1 mRNA expression with respect to GBM transcriptional subclasses. Oneway ANOVA identified the proneural GBM subtype, among which isocitrate dehydrogenase 1 and 2 (mIDH1/2) mutation is most common, with significantly lower IDO1 mRNA levels ( Fig. 3A ; P < 0.05; Supp. Table 5 ). Decreased IDO1 expression was also evident in mIDH1/2-associated grade III and IV glioma specimens ( Fig. 3B , P < 0.0001, Supp. Table 5 ). Given the established relationship between IDH1 mutation and cytosine hypermethylation in glioma (29, 30) , we also analyzed genomic CpG motifs for DNA methylation throughout the human IDO1 gene locus. TCGA analysis of the DNA methylation status identified 3 CpG loci within the human IDO1 gene (locus 1: cg10262052, 1500bp of upstream transcription start site; loci 2 and 3: cg0846577, cg24188163, gene body). Methylation was increased at 2 of the 3 CpG loci in mIDH1/2 grade II and III glioma (Fig. 3C) . In contrast, methylation patterns did not significantly change at any CpG locus among GBM specimens, confirming that, while lower glioma grade IDO1 expression is significantly affected by mIDH status, independent mechanisms appear to regulate IDO1 mRNA levels in GBM.
Due to IDO1 activity acting as an immunosuppressant, we examined IDO1 expression with respect to the expression of genes that influence immune response. Using (Fig. 3D, E) . These results suggest that increased IDO1 expression is most evident in tumors expressing additional immunosuppressive factors.
We also examined IDO1 expression with respect to immune cell infiltrates in tumor, including the markers: (i) CD14, HLA-DR, CD312, CD115, CD163, CD204, CD301, CD206 associated with tumor-associated macrophages (TAM), (ii) CD14, CD11b, CD33, Arg1 associated with myeloid-derived suppressor cells (MDSC), and (iii) CD11b, CD16, CD66b and ELANE associated with neutrophils. Correlation analyses showed that GBM-derived IDO1 mRNA levels positively correlate with the expression of all of the cell-type specific marker genes (Supp. Fig. 4A, B ; P < 0.001).
Regulation of IDO1 expression in glioblastoma
In many tissues, IDO1 expression is undetectable (20) , but rapidly induced and made detectable by pro-inflammatory stimuli (31) . Due to the multiple interferonstimulated response elements (ISRE) in the promoter region of IDO1, treatment of in vitro-cultured human GBM cells with the T cell effector pro-inflammatory cytokine, IFNγ (IFNG), leads to robust IDO1 mRNA and protein expression (32, 33 (Fig. 4A) . In contrast, of the 160 GBM specimens with detectable IDO1 expression, >50% (n=94) were absent for IFNG. Strikingly, 43% (n=69) of GBM specimens were absent for both IFNG and IFN. When the 172 total GBM samples were further stratified into IFNG/IFN-expressing, versus -non-expressing groups, no difference was found among IDO1 mRNA levels (Fig. 4B) , nor did this stratification yield any correlation with GBM patient survival (Fig. 4C) .
TCGA analysis for human T cell-specific surface marker, CD3E, as well as Tcassociated surface marker, CD8A, was next assessed among the 172 patient-resected GBM samples and its correlation with IDO1, IFNG and patient survival. Sample stratification identified that 56% of GBM possess low CD3E and CD8A mRNA levels, 29% consist of low CD3E with high CD8A mRNA levels and 15% contain high CD3E and high CD8A mRNA levels (Fig. 4D) . Notably, high CD3E and CD8A mRNA levels were correlated with higher IDO1 and IFNG mRNA levels, as well as decreased patient survival (P < 0.01). These results suggest that greater T cell infiltration of tumor is associated with higher IDO1 and IFNG expression, as well as lower overall survival of GBM patients.
Based on the well-characterized association of activated CD8 + T cells and IFNγ expression, we investigated potential associations between the expression of IFNG, CD3E and CD8A mRNA. Frequency analysis indicated that GBM specimens lacking in IDO1 expression also lacked detectable CD3E and CD8A T cell signatures (n=12), irrespective of tumor IFNG expression (Fig. 4E) . Conversely, GBM specimens with high CD3E and CD8A transcript levels expressed detectable IDO1, with a higher frequency of specimens co-expressing IFNG (n=20). We also examined the association between
+ T cells and Treg (Fig. 4F) , as well as IDO1 mRNA and Treg (Fig. 4G) , confirming a positive relationship among both correlative groups.
T cells directly regulate IDO1 expression in human GBM
To further explore associations between T cells and IDO1 expression in GBM, humanized immunocompetent mice (hNSG; NSG-SGM3-BLT) were intracraniallyengrafted with human patient-derived GBM xenografts (PDX) 12 or 43 and treated with or without T cell depleting antibodies. Analysis of isolated GBM tumors, draining cervical lymph nodes (cLN) and spleen revealed the presence of both CD4 + and CD8 + human T cells that were significantly decreased when mice were co-administered T celldepleting antibodies (Fig. 5A,B) . The analysis of humanized immunocompetent mice engrafted U87 GBM revealed a predominantly human leukocyte composition in mouse spleen that was reflected in both the myeloid and lymphoid immune cell compartments (Supp. Fig. 5A ). Similar to mice engrafted PDX GBM, analysis of U87 tumors confirmed the presence of human T cells in the GBM (Supp. Having validated the presence of human T cells in humanized mice with intracranial human PDX or U87 GBM, we further explored the hypothesis that T cells directly increase IDO1 expression in human glioma. Results from mice depleted for
CD4
+ and CD8 + T cells confirm that immune cell neutralization does not affect tumor growth (Supp. Fig. 7) , and that T cell depletion decreases tumor IDO1 mRNA levels (P < 0.001, respectively) ( (Fig. 5D) . In vitro GBM patient T cell:U87 GBM cell co-cultures confirmed that IDO1 is induced by activated T lymphocytes in an IFNγ-dependent manner ( Fig. 5E ; P < 0.001; Supp. To evaluate relationships between IDO1 expression and tumor-infiltrating T lymphocytes, our use of humanized immunocompetent (NSG-SGM3-BLT) mice intracranially-engrafted with human GBM showed that tumor IDO1 expression is influenced by infiltrating CD4 + and CD8 + T cells. In contrast to the general assumption that IFNγ is the primary regulator of IDO1 expression, our analysis of 172 patientresected GBM revealed that 59% of tumor specimens are undetectable for IFNG (Fig.   4A ). Coincidently, PDX12 tumor IDO1 expression increased in a T cell-dependent manner that was not associated with a commensurate increase in IFN levels, in situ (Fig.   5C ). These findings confirm the existence of additional mechanisms responsible for IDO1 gene expression in GBM and is the subject of an ongoing investigation by our
Research. group. Therefore, we could conclude that, IFNG is sufficient, but not required, for increasing IDO1 levels in human GBM.
We found significant correlations between GBM IDO1 levels, decreased patient survival, and increased marker expression for Tc and Treg (Fig. 4D, E, F, G This model highlights the negative repercussions of inflammatory enhancement in human GBM and is supported by the data in Fig. 3A, B, showing the inverse association between the presence of mIDH and decreased intratumoral IDO1 levels. Given that mIDH suppresses CD8
+ Tc cell accumulation in glioma (37), in addition to the favorable prognosis it carries for GBM patient survival (38) , it is tempting to speculate that the mIDH suppression of GBM-infiltrating Tc increases patient survival by virtue of the additional suppression of IDO1 and Treg accumulation in those patient tumors.
Our observations suggest that future immunotherapeutic strategies incorporating IDO1 inhibition into a GBM patient treatment regimen may be more effective in treating classical, mesenchymal and neural GBM subtypes, when compared to the lower IDO1-expressing proneural GBM and glioma grades II and III. These data further infer that GBM patients with high baseline tumor-infiltrating T cell levels, or those who enroll on T 
cell enhancing therapeutic treatments, may maximally benefit from the addition of an IDO1 inhibitor. Our data also indicate a gene expression correlation between IDO1 and other mediators of immunosuppression (Fig. 3D, E) , highlighting the potential for enhancing anti-tumor effects when combining IDO1 inhibition with a blockade of multiple immune checkpoint targets.
In conclusion, we show for the first time that IDO1 mRNA levels are a useful, sensitive and prognostic predictor of grade II -IV glioma patient survival. We also introduce a new, enzymatically active modified U87 human GBM cell line that expresses an C-terminus HA tag conjugated to human IDO1 (Supp. Fig. 2) . We further present novel data showing differential IDO1 exon expression among patient-resected GBM ( Fig.   3 ; Supp. Table 2 ), highlighting complex transcriptional mechanisms that are likely associated with the expression of multiple isoforms. Analysis of IDO1 expression in GBM isolated from humanized mice engrafted PDX43 and U87, versus PDX12 GBM, provide new comparative platforms for investigating IFN-independent mechanisms of IDO1 regulation by tumor-infiltrating T cells. Given the past preclinical strategies demonstrating the survival benefit of pharmacologic IDO1 blockade in preclinical brain tumor models (39) , in addition to clinical trials evaluating IDO1 targeting strategies in glioma patients (NCT02052648, NCT02764151), the data collectively suggest that future treatment approaches designed to enhance T cell-mediated antitumor immunity may maximally benefit from the further addition of an IDO1 inhibitor.
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